BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Metronomic Low-Dose Oral Cyclophosphamide and Methotrexate

**Protocol Code**  
BRAVCMPO

**Tumour Group**  
Breast

**Contact Physician**  
Dr. C. Lohrisch

**ELIGIBILITY:**
- pretreated metastatic breast cancer with ECOG performance status 0, 1, or 2 and greater than 3 month life expectancy
- previously untreated metastatic breast cancer in patients unsuitable for other chemotherapy drugs due to excess toxicity risk

**EXCLUSIONS:**
- severe renal dysfunction, creatinine clearance less than 10 mL/min
- severe hepatic dysfunction, bilirubin greater than 85 or AST greater than 3 x ULN

**TESTS:**
- Baseline: CBC and platelets, serum creatinine, bilirubin, liver enzymes
- Before each treatment: CBC and platelets, bilirubin, AST
- If clinically indicated: creatinine, ALT, alkaline phosphatase

**PREMEDICATIONS:**
- Antiemetic protocol for low emetogenic chemotherapy protocols (see SCNAUSEA)

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td>50 mg orally once daily continuously</td>
<td>PO</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>2.5 mg orally BID on Days 1 and 2 each week</td>
<td>PO</td>
</tr>
</tbody>
</table>

1 cycle = 4 weeks

Repeat every 28 days x 6-8 cycles. Responding patient may be continued on treatment at the discretion of the treating physician. Discontinue if no response after 2 cycles or unacceptable toxicity.
DOSE MODIFICATIONS:

1. Hematological

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets (x10^9/L)</th>
<th>Dose (all drugs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.5 and greater than or equal to 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>1-1.49 or 75-99</td>
<td>proceed at 50%</td>
<td></td>
</tr>
<tr>
<td>less than 1 or less than 75</td>
<td>delay, then dose at 50% after recovery</td>
<td></td>
</tr>
</tbody>
</table>

2. Renal dysfunction

For Methotrexate:

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than 30</td>
<td>100%</td>
</tr>
<tr>
<td>15-30</td>
<td>50%</td>
</tr>
<tr>
<td>less than 15</td>
<td>omit</td>
</tr>
</tbody>
</table>

\[
GFR = \frac{N \times (140 - \text{Age}) \times \text{weight (kg)}}{\text{Serum Creatinine (micromol/L)}}
\]

* For males N = 1.23; for females N=1.04

For Cyclophosphamide: Renal failure may lead to reduced excretion of metabolites and increased toxicity. Significant falls in clearance with increased exposure have been documented in patients with renal impairment. Severe renally impaired patients (CrCl less than 10 mL/min) are at particular risk and should be treated at reduced dose and with caution. See BCCA Cancer Drug Manual.

3. Hepatic dysfunction: Dose modification required for methotrexate.

<table>
<thead>
<tr>
<th>Bilirubin (micromol/L) or AST (units/L)</th>
<th>Methotrexate Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>50-85 or 3 x ULN</td>
<td>2.5 mg daily on Days 1 and 2</td>
</tr>
<tr>
<td>greater than 85 or greater than 3 x ULN</td>
<td>2.5 mg daily on Days 1 and 2</td>
</tr>
<tr>
<td></td>
<td>omit</td>
</tr>
</tbody>
</table>
PRECAUTIONS:
1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively. Refer to BCCA Febrile Neutropenia Guidelines.

Call Dr. Caroline Lohrisch or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 01 Mar 2012
Date revised: 01 Jul 2012 (revised renal dose modifications, references updated)

References: